Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy of Non-Hodgkin’s Lymphoma

9/25/01

Click here to start

Table of Contents

Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy of Non-Hodgkin’s Lymphoma

Presentation Agenda

Zevalin™ (ibritumomab tiuxetan):Proposed Indication

Non-Hodgkin’s Lymphoma

Zevalin Regimen

Clinical Basis for BLA

Zevalin™ (ibritumomab tiuxetan):Summary

IDEC Investigators

IDEC Investigators (cont.)

Presentation Agenda

Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy of Non-Hodgkin’s Lymphoma

Treatment of Relapsed or Refractory LG/F/T NHL

Toxicities of Commonly Used Regimens

Treatment of Relapsed or Refractory LG/F/T NHL

Rationale for Radioimmunotherapy in NHL

Critical Factors for Successful RIT

Zevalin Phase I and I/II Conclusions

Zevalin Phase I/II Study (N = 51)

Imaging and Dosimetry

Disease Status (cont.)

Response Assessment Protocol-Defined Response Criteria

Response Assessment International Workshop Response Criteria

Zevalin vs Prior Therapy Analysis

Zevalin vs Prior Rituximab or Last Chemotherapy (N = 54)

Phase III Nonhematologic AEs (N = 143)

Absolute Neutrophil Counts (N = 349)

Duration of Hematologic Toxicity

Mortality (N = 349)

Subsequent Bone Marrow Transplantation

Summary (cont.)

Presentation Agenda

Author: Lynn Stine